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Caspases-1, -4, and -5 are cysteine-dependent 
proteases that have essential roles in phagocytic 
cells of the innate immune system. Pathogen- and 
damage-associated molecular patterns (PAMPs 
and DAMPs) are recognized by the NOD-like 
receptor protein 3 (NLRP3) inflammasome, 
which is responsible for cleaving the zymogen 
pro-caspase-1 into its active tetrameric form.27 
Once activated, caspase-1 produces the 
inflammatory cytokine interleukin-1β (IL-1β) 
from its precursor, which is secreted to recruit 
other circulating immune cells into the affected 
tissue. The inflammatory cascade is complicated 
by the involvement of caspases-4 and -5, which 
produce another inflammatory cytokine, 
interleukin-1α (IL-1α) and also indirectly activate 
pro-caspase-1.1 These enzymes have been 
observed to be induced upon sensing pathogenic 
species like liposaccharides (LPS); though, like 
the canonical pathway, the mechanism of 
activation is not fully understood.24 
 
Constitutive activity of the canonical 
NLRP3/caspase-1 pathway leads to harmful 
pyroptotic responses that are a characteristic of 
inflammatory diseases like lupus, psoriasis, and 
 
ABSTRACT Inflammatory caspases-1, -4, and -5 play critical roles in mediating the innate immune 
response to pathogen- and damage-associated molecular patterns. Caspase-1 produces the cytokine 
interleukin-1β (IL-1β), while caspases-4 and -5 activate the NOD-like receptor protein 3 inflammasome 
via the non-canonical pathway. Overactivation of these enzymes is associated with an increased risk for 
inflammatory diseases such as lupus, psoriasis, and rheumatoid arthritis. Small molecule inhibitors 
(SMIs) have been developed to attenuate the production of IL-1β, but unfavorable bioavailability and 
toxicity have provided an insurmountable barrier in clinical trials. This work is concerned with 
delivering an overview of current progress in the synthetic design of SMIs of the inflammatory caspases. 
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rheumatoid arthritis. Currently, there are several 
protein-based treatments that decrease the effects 
of IL-1β, such as anakinra, canakinumab, and 
rilonacept.8 These proteins act as IL-1β 
antagonists, monoclonal antibodies, and soluble 
receptors, respectively (Figure 1). While anakinra 
blocks the cytokine’s binding site on the IL-1β 
receptor protein, canakinumab is an antibody 
treatment that neutralizes IL-1β instead of 
competing with it at the binding site. Rilonacept 
is a receptor protein designed to bind IL-1β; 
however, since it is soluble in blood plasma and 
not integrated into the membrane of a leukocyte, 
any cytokines lured to this protein do not 
contribute to the inflammatory response. 
Although effective, these treatments are 
expensive to produce and must be administered 
via injection due to the harsh environment of the 
stomach, which prevents an optimal oral 
alternative. Additionally, the half-lives of these 
proteins are not ideal. For instance, anakinra 
degrades quickly and requires frequent injections, 
while the biostability of canakinumab confers a 
long half-life that leaves the individual at risk for 
infections.4 
 
The disadvantages of protein-based treatment 
methods have made small molecule inhibitors 
(SMIs) of the inflammatory caspases attractive 
research prospects. This approach directly 
decreases the activation and secretion of IL-1β 
rather than merely disguising the cytokine’s 
effects. Traditionally, potent inhibitors of 
caspases have employed an electrophilic 
functional group to trap the essential thiolate 
residue in the active site. However, SMIs have 
since broadened to target allosteric sites as well. 
Candidates that demonstrate compatibility with 
more than one caspase have also been discovered. 
Currently, all SMIs that have reached clinical 
trials have failed to pass them.13 Herein, a review 
is presented of currently known SMIs of 
caspases-1, -4, and -5 with a focus on structural 
themes.    
 
INHIBITORS OF CASPASE-1 
Most known inhibitors of caspase-1 are 
peptidomimetic and bind at the aspartate-specific 
active site. The proteolytic residue Cys285 can be 
trapped by a carbonylic group in either a 
reversible or irreversible manner, stopping the 
cleavage of pro-IL-1β. The structure of a 
competitive caspase-1 inhibitor can be 
generalized as having a core, P4-P2, and prime 
side fragment (Figure 2).  
 
The core fragment contains an aspartate moiety 
that acts as an electrophilic trap for the proteolytic 
thiolate. The prime side, which is not present in 
all inhibitors, adds additional stabilization in the 
active site by anchoring the substrate to the 
interior hydrophobic pocket of the enzyme. The 
Figure 1. Decreased effects of IL-1β signaling via 
protein drugs. Displayed are the three approved 
treatments for targeting caspase-activated IL-1β: 
blocking the cytokine’s receptor (anakinra), 
destroying the cytokine (canakinumab), and luring the 
cytokine to a soluble decoy receptor (rilonacept).  
 
Figure 2. General structure of a competitive inhibitor 
of caspase-1. The scaffold contains an aspartate 
residue (core fragment) with extensions that interact 
with the S2-S4 region (P4-P2 fragment) and the interior 
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P4-P2 fragment describes the structure of one of 
the first-identified reversible inhibitors, Ac-
YVAD-CHO.14 The tyrosine (P4), valine (P3), and  
alanine (P2) moieties appear to interact with 
caspase-1 through hydrophobic interactions of 
the side chains and hydrogen bonds of the 
backbone amides. (Figure 3). However, analysis 
via X-ray crystallography has demonstrated that 
the hydrogen bonds formed by the backbone 
amides of the P4-P2 fragment are not required for 
binding, prompting designs that involve less 
restricted peptidomimetic derivatives.18  
 
A nearly invariable characteristic of all potent 
caspase-1 inhibitors is the presence of an 
electrophilic warhead. In both reversible and 
irreversible inhibition, the side chain of Cys285 
undergoes a nucleophilic attack at the carbonylic 
carbon of the inhibitor. In reversible inhibition, 
the tetrahedral intermediate is momentarily 
stabilized by the oxyanion hole until collapsing 
and breaking its covalency with the inhibitor.  An 
analogous intermediate characterizes the 
irreversible mode of inhibition. However, since 
the SMI is equipped with a leaving group, it can 
irreversibly trap the proteolytic cysteine residue 
by detaching its prime side.   
Two of the first identified inhibitors of caspase-1 
are the peptidic aldehydes 1 and 2 (Figure 4).2, 21  
These SMIs offer reversible interactions with the 
protease that closely resemble the natural 
substrate via an aspartate residue at the P1 
position, exhibiting Ki values of 0.76 and 0.056 
nM, respectively. The aromatic residues at the P4 
position are known to interact strongly with 
His342 and Pro343, two residues involved in 
inhibitor binding.20 Despite significantly 
decreasing the levels of IL-1β in rats17, neither of 
these SMIs demonstrate an acceptable cellular 
permeability in human cells.  
 
Although inhibitors with tetrapeptide motifs like 
1 and 2 are highly compatible with the active site 
of caspase-1, they are not promising drug 
candidates due to poor cell permeability, toxicity, 
stability, and selectivity.3 Such a reality has 
prompted the design of less restricted 
peptidomimetic structures by using these two 
inhibitors as the epicenters of optimization. Since 
1 and 2 are both potent inhibitors of caspase-1 
despite having chemically different amino acid 
Figure 3. Peptidomimetic interactions with caspase-1. PyMOL entry 5mtk. Caspase-1 interacts with an inhibitor 
through its S1 and S2-S4 regions, displayed in yellow and orange, respectively. The side chain of the putative catalytic 
residue Cys285 is showcased. The hydrophobic pocket is displayed in purple.  
3
Ahlers: Small Molecule Inhibitors of Inflammatory Caspases-1, -4, and -5
Published by Via Sapientiae, 2021
residues at the P2 and P3 positions, this suggests 
that this part of the inhibitor can be varied to 
attain an improved pharmacological profile.  The 
structure of the pro-drug pralnacasan 3 is one 
such variant. The nonpolar cyclic constraints in 
the P2 and P3 positions offer increased 
bioavailability and stability without affecting its 
potency. Indeed, 3 has caused decreased levels of 
IL-1β from mononuclear cells of LPS-challenged 
mice.22 The drug advanced to late-stage clinical 
trials before its candidacy was withdrawn due to 
toxicological concerns present in the livers of the 
murine test subjects.15  
 
The P2-P3 sites have also been designed with 
acyclic components. Succinic acid amides like 4 
have shown promising bioavailability in addition 
to potent inhibition of caspase-1.5 Like 1-3, 
compound 4 has a truncated prime side fragment, 
possessing only an ethyl acylal pro-drug 
component. The pro-drug form was found to be 
essential for bioavailability. The ionization of the 
aspartate residue confers an inability to cross the 
lipophilic bilayer.  
 
Interestingly, docking studies of 4 revealed that 
the succinic acid amide scaffold does not interact 
with the S3 region of caspase-1 and instead 
prefers to stabilize itself through hydrogen 
bonding with the solvent. This finding provided 
further evidence that the P2-P3 components of a 
caspase-1 inhibitor are not essential for binding 
to the enzyme. Thus, they should be adjusted to 
optimize the alignment of the aromatic P4 
position in the active site. Analogs of 4 that 
employed cyclized P2-P3 components were 
substantially less potent. Since cyclization of the 
analogous positions in 3 did not cause a similar 
problem, it can be inferred that the effects of 
cyclization depend on the overall structure of the 
Figure 4. Known inhibitors of caspase-1. 
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inhibitor and cannot be generalized as having 
positive or negative effects on inhibitory potency.  
Compound 5 is another reversible inhibitor. The 
aromatic residues that interact with the S4 region 
of caspase-1 are separated by several methylene 
groups. Cleverly, this SMI was optimized 
through a fragment-assembly approach. First, a 
P1 fragment that contained a terminal thiol was 
bound to the active site; then, a disulfide bond 
formed with an analogously modified P3/P4 
fragment only if this fragment was able to bind to 
the respective region of caspase-1.19 Although 
neither fragment inhibits the protease by itself, a 
submicromolar potency is observed when they 
are combined. In the final structure of 5, the 
disulfide bond is replaced with a hydrocarbon 
skeleton. The SMI shows appreciable inhibition 
of both caspases-1 and -5 with respective Ki 
values of 0.016 and 2.03 µM and thus can be 
classified as a pan-inhibitor.   
 
The compatibility of an inhibitor with two or 
more of the inflammatory caspases is no small 
feat. Indeed, compounds 1-4 have not been 
reported to have any effect on the activity of 
caspases-4 and -5, making compound 5 an 
attractive design for a reversible inhibitor. Broad 
inhibition of caspases-1, -4, and -5 is preferred, 
given that all three are influential in the 
production of IL-1β. By inhibiting two or more 
with one inhibitor, this SMI is more likely to 
show successful results in clinical trials. 
However, this challenge becomes increasingly 
difficult upon considering that the inhibitor must 
also be caspase-specific. If the SMI is 
promiscuous with all catalytic thiolates, including 
the apoptotic caspases, or attractive to other 
cellular nucleophiles, its utility will be 
compromised.  
 
Unlike 1-5, compound 6 is an irreversible 
inhibitor. This SMI is derived from isoquinoline-
1,3,4-trione, which acts as the leaving group upon 
trapping the catalytic residue of caspase-1. Broad 
inhibition of the inflammatory caspases has been 
observed with the SMI, but it is selective for this 
family and does not act as a general protease 
inhibitor.16 Remarkably, 6 does not possess the 
essential aspartic residue at P1. The lack of this 
residue leads to slow binding to the aspartate-
specific caspases, but since the binding is 
irreversible, it cannot be undone after doing so.  
The SMI also shows acceptable cellular 
penetration due to its largely hydrophobic 
scaffold. Structures like 5 and 6, which link the 
P1 and P4 regions via methylene groups, may be 
useful in broadly inhibiting the caspase family. 
Currently, it does not appear that analogs of these 
structures have been extensively pursued. 
Therefore, optimization of these scaffolds could 
afford promising candidates. 
 
As previously stated, it is not uncommon for the 
prime side of a caspase inhibitor to be missing or 
simply used as a leaving group. Compounds 7 
and 8 are unique in that they are inhibitors that 
were developed by optimizing the prime side 
interactions with caspase-1.6 Both are remarkably 
potent, recording Ki values of 2 and 1 pM, 
respectively. The former is an acyloxyalkyl 
ketone that possesses a bulky hydrophobic and 
aromatic prime side, which anchors the SMI to 
the protease’s hydrophobic interior. SMI 7 also 
exhibits bimodal inhibition, decreasing caspase-1 
activity via reversible and irreversible inhibition. 
Interestingly, SAR studies revealed that 
optimizing the potency of the ester favored the 
irreversible mechanism.  Compound 8 is a 
hydroxamate analog that exhibits only reversible 
inhibition regardless of the potency. 
 
Although diverse in structure, compounds 1-8 
can be described using the general structure of 
caspase-1 inhibitors (with the exception of 6). 
They contain an aspartate residue at the P1 
position and have modifications in the P2-P4 and 
prime side regions. Recently, there has been a 
focus on caspase-1 SMIs that significantly 
deviate from the traditional structure. Indeed, 
inhibitors that occupy similar spatial areas as 1 
and 2 but are not peptidomimetic are attractive 
candidates, given the poor biostability associated 
with hydrolysable species. Compounds 9 and 10 
are examples of such candidates, as neither have 
an aspartate residue nor many enticing peptide 
bonds that can allure cellular nucleophiles. SMI 9 
was optimized for the active site through the 
variation of the substituents on the 
diaminopyrimidine derivative.9 No covalent 
interactions with Cys285 were reported despite 
the binding of 9 to the active site. Similarly, LC-
MS analysis of caspase-1 after treatment with 
5
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compound 10 did not suggest any covalent 
interactions either.10 Notably, this compound 
inhibits caspase-1 (Ki = 48 nM) even with the 
addition of excess substrate14, suggesting that it 
likely operates via an allosteric mechanism. 
Though allosteric inhibitors of caspase-1 do exist, 
they are rare.  
 
Compounds 9 and 10 likely offer insight into the 
future structure of a successful drug candidate for 
caspase-1 inhibition. These SMIs have a scaffold 
that should be able to readily permeate the 
cellular membrane and evade the attention of 
cellular nucleophiles. Therefore, optimizing 9 
and 10 and further elucidating their mechanisms 
of inhibition are useful research targets.  
 
INHIBITORS OF CASPASES-4 AND -5 
Of the SMIs discussed so far, most have not been 
pan-caspase inhibitors. With the exception of 5 
and 6, the target of inhibition has been 
exclusively caspase-1. Impeding the activity of 
this enzyme has received significantly more 
attention than its inflammatory counterparts, 
caspases-4 and -5. The reason for this trend is that 
the pathway that converts pro-IL-1β into its 
active cytokine form is the prototypical innate 
immune response. Additionally, the crystallized 
structure of caspase-4 has only recently been 
deposited on online databases, limiting the use of 
docking studies to model interactions. The 
crystallized structure of caspase-5 remains 
outstanding; though, sequence alignment with 
caspase-1 has been performed to predict its native 
form. 
Both caspases-4 and -5 are known to activate the 
NLRP3 inflammasome through the noncanonical 
pathway and also regulate the secretion of 
another cytokine, IL-1α.26 Therefore, from a 
therapeutic perspective, it may be impractical to 
decrease inflammation by only inhibiting 
caspase-1. Fortunately, the genetic sequence 
among the inflammatory caspases is highly 
conserved, which allows for shared 
characteristics among putative SMIs, such as 
aspartate-specificity and hydrophobicity in the S4 
region.25 
 
When caspases-4 and -5 were discovered, it was 
ascertained that the proteases must have similar 
substrate preferences due to pan-inhibition via the 
cowpox virus-derived inhibitor, CrmA.11 Shortly 
after, peptidic SMIs that are analogous to the 
putative caspase-1 inhibitor Ac-YVAD-CHO 
were identified. Compounds 11 and 12 are 
inhibitors of caspases-4 and -5, respectively; 
though, both show a certain degree of pan-
inhibition (Figure 5).  The structures of these 
SMIs are Z-LEVD-FMK and Z-WEHD-FMK. 
These SMIs diffuse across the lipid bilayer of the 
cell membrane more easily than 1 and 2 due to the 
esterification of the hydrophilic carboxy groups 
on glutamate and aspartate. It should be noted that 
peptidic aldehyde versions of 11 and 12, like 1 
and 2, have also been identified as possessing 
inhibitory effects on their respective caspase.12 It 
is not surprising that, like caspase-1, the activity 
Figure 5. Known inhibitors of caspases-4 and -5. 
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of caspases-4 and -5 can be suppressed by species 
that closely mimic a natural peptide. The active 
sites are highly conserved and thus readily bind 
to these structures. Such a luxury comes at the 
cost of biostability and other problems, as 
previously stated. 
 
SMIs like 13 and 14 are not as obvious as the 
substrate-based 11 and 12 but are remarkably 
promising allosteric prospects. Caspases, 
including both the inflammatory and apoptotic 
players, have a cavity at the dimeric interface of 
the heterodimers, which is located 15 Å away 
from the active site. In regard to caspase-1, 
Cys331 is found within this region and can be 
allosterically trapped.23 When such process 
occurs, a salt bridge between Arg286 and Glu390 
that aligns the active site for catalysis is broken. 
Fortunately, all three of these residues are 
conserved throughout the caspase family, 
denoting a common regulatory mechanism. It 
should be noted that this mechanism is likely 
responsible for the allosteric inhibition of 
caspase-1 by 10.  
 
Compound 13 is a naphthyl-thiazole-containing 
SMI. Upon treatment of caspase-5 with 13, both 
the turnover rate and binding affinity of the 
substrate decreased. Such an observation is 
consistent with a mechanism of allosteric 
regulation. This SMI therefore likely acts as a 
negative regulator molecule and causes a 
conformational change in caspase-5.7 No effects 
were observed on caspase-1, indicating an 
appreciable selectivity. Thus far, SMIs 1-13 have 
shown no or partial pan-inhibition of the 
inflammatory caspases. Compound 14 deviates 
from this trend, demonstrating Ki values of 16, 8, 
and 16 nM for caspases-1, -4, and -5, 
respectively.10 This triamino pyrimidine 




The known inhibitors of caspases-1, -4, and -5 
have evolved from solely substrate-based 
molecules into less restricted peptidomimetic 
structures and, recently, allosteric regulators. It is 
thus clear from the trends in current research on 
the inflammatory caspases that the eventual 
successful therapeutic candidate will not closely 
mirror a natural peptide. While these SMIs are 
useful for research purposes, they are not viable 
pharmaceutic candidates due to a lack of stability 
and selectivity. Therefore, SMIs that attract less 
undesirable side reactions will likely be critical to 
surpassing clinical trials. This hurdle favors 
allosteric regulators, like compounds 10, 13, and 
14. The conserved dimer interface among the 
caspases could allow for selective pan-inhibition 
that would effectively shut off the innate immune 
response, temporarily alleviating the pain of the 
discussed pathologies. Although further work 
should be performed to optimize the allosteric 
regulators, a challenge will be the compact pocket 
of the dimer interface that may limit the extent of 
structural modifications.  
 
Inhibitors of caspase-1 have been the focus of 
recent research. While there are over one-
hundred known SMIs of caspase-1, there is a 
small list for both caspases-4 and -5. As more 
SMIs of these caspases are discovered, 
optimization will be facilitated. Until recently, 
little information has been available on public 
databases regarding the quaternary structures of 
these proteases. Although homology modeling is 
useful for docking studies, it is not as helpful as a 
crystallized model. Therefore, it stands to reason 
that inhibitors or regulators of caspases-4 and -5 
will become more available in the coming years. 
With some good fortune, a therapeutic SMI of the 
inflammatory caspases can be expected within 
the next decade. Although the same was said a 
decade prior, a focus on optimizing a non-
traditional structure, like an allosteric regulator, 
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